Covid-19 vaccines have brought billions of dollars to the coffers of pharmaceutical companies. Germany's BioNTech, maker with partner Pfizer of the pioneering mRNA jab, raised its vaccine revenue forecast for 2021 in its latest earnings report on Monday.
The companies — Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson — reported considerable turnovers in first half of the year, AFP reports.
Pfizer has earned more than its competitors, raking in $10.8 billion (9.2b euros) in the first half of this year. The US company has raised its outlook for 2021, expecting to make $33.5b in sales for the full year.
BioNTech reported revenues of $7.3b euros in the first half. Unlike its larger partner, the company's only product on sale is the coronavirus vaccine. Likewise, Moderna reported turnover of $5.9b in the first six months of the year. It expects to make $20b in revenues thanks to the vaccine this year.
AstraZeneca's Covid jab generated $1.2b in sales in the first six months of the year. While J&J reported $264m in sales and expects to make $2.5b for the full year.
